BillionToOne
Update in progressBLLN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
BillionToOne, Inc. is a precision diagnostics company that quantifies biology to enable molecular diagnostics. Its molecular counting platform detects and measures DNA molecules at the single-count level to improve disease detection. The company offers UNITY Complete, a non-invasive prenatal screen from a maternal blood draw for aneuploidies and recessive conditions; Northstar Select, a liquid biopsy showing tumor mutations; and Northstar Response, a methylation assay tracking cancer burden and treatment response without biopsy. Founded 2016, headquartered in Menlo Park, California.
Company score
- Sentiment
- 0.45
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Oguzhan Atay Ph.D.
- Founded2016
- Employees713
- Websitewww.billiontoone.com
Identifiers
- ISINUS0901681058
- FIGIBBG00NR7JXT0